A detailed history of Acadian Asset Management LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 3,100,994 shares of CTMX stock, worth $3.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,100,994
Previous 2,728,569 13.65%
Holding current value
$3.1 Million
Previous $3.32 Million 9.96%
% of portfolio
0.01%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.12 - $1.51 $417,116 - $562,361
372,425 Added 13.65%
3,100,994 $3.66 Million
Q2 2024

Aug 06, 2024

BUY
$1.21 - $5.13 $45,664 - $193,601
37,739 Added 1.4%
2,728,569 $3.32 Million
Q1 2024

May 10, 2024

BUY
$1.41 - $2.74 $62,942 - $122,313
44,640 Added 1.69%
2,690,830 $5.86 Million
Q3 2023

Nov 13, 2023

SELL
$1.26 - $1.87 $9,306 - $13,811
-7,386 Reduced 0.28%
2,646,190 $3.41 Million
Q3 2022

Nov 14, 2022

BUY
$1.23 - $1.97 $1 Million - $1.6 Million
814,350 Added 44.28%
2,653,576 $3.85 Million
Q2 2022

Aug 09, 2022

BUY
$1.53 - $2.89 $1.46 Million - $2.76 Million
954,119 Added 107.8%
1,839,226 $3.37 Million
Q1 2022

May 12, 2022

BUY
$2.67 - $4.68 $1.27 Million - $2.22 Million
473,885 Added 115.24%
885,107 $2.36 Million
Q4 2021

Feb 10, 2022

SELL
$3.87 - $7.39 $1.12 Million - $2.14 Million
-289,768 Reduced 41.34%
411,222 $1.78 Million
Q3 2021

Nov 12, 2021

SELL
$4.32 - $6.43 $1.5 Million - $2.24 Million
-348,149 Reduced 33.18%
700,990 $3.57 Million
Q2 2021

Aug 11, 2021

BUY
$6.33 - $9.91 $646,786 - $1.01 Million
102,178 Added 10.79%
1,049,139 $6.64 Million
Q1 2021

May 11, 2021

BUY
$6.6 - $9.0 $1.71 Million - $2.33 Million
259,071 Added 37.66%
946,961 $7.32 Million
Q4 2020

Feb 11, 2021

BUY
$6.47 - $7.9 $683,717 - $834,832
105,675 Added 18.15%
687,890 $4.51 Million
Q3 2020

Nov 09, 2020

BUY
$6.55 - $8.83 $1.87 Million - $2.53 Million
286,216 Added 96.69%
582,215 $3.87 Million
Q2 2020

Aug 12, 2020

BUY
$7.4 - $14.64 $176,238 - $348,666
23,816 Added 8.75%
295,999 $2.47 Million
Q1 2020

May 11, 2020

BUY
$3.61 - $8.6 $247,794 - $590,312
68,641 Added 33.72%
272,183 $2.09 Million
Q4 2019

Feb 06, 2020

BUY
$5.17 - $8.91 $568,229 - $979,289
109,909 Added 117.38%
203,542 $1.69 Million
Q3 2019

Nov 07, 2019

SELL
$7.38 - $12.25 $414,822 - $688,560
-56,209 Reduced 37.51%
93,633 $691,000
Q2 2019

Aug 08, 2019

BUY
$9.35 - $11.41 $276,460 - $337,370
29,568 Added 24.58%
149,842 $1.68 Million
Q1 2019

May 09, 2019

BUY
$9.5 - $19.16 $1.14 Million - $2.3 Million
120,274 New
120,274 $1.29 Million
Q3 2018

Oct 30, 2018

SELL
$18.04 - $26.41 $917,929 - $1.34 Million
-50,883 Closed
0 $0
Q2 2018

Jul 24, 2018

SELL
$21.38 - $29.68 $479,040 - $665,010
-22,406 Reduced 30.57%
50,883 $1.16 Million
Q1 2018

Apr 12, 2018

BUY
$21.76 - $34.22 $1.59 Million - $2.51 Million
73,289 New
73,289 $2.09 Million
Q4 2017

Jan 18, 2018

SELL
$19.0 - $23.09 $30,552 - $37,128
-1,608 Closed
0 $0
Q3 2017

Oct 13, 2017

BUY
$13.53 - $18.17 $21,756 - $29,217
1,608
1,608 $29,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.